Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients

Han, Xinyuan; Chen, Chunyan; Cheng, Gong; Xie, Cui Wei; Yang, Meng; Shou, Xiling; Sun, Changqing

doi:10.1016/j.cyto.2015.02.019

Cited by 33 publications

(37 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pericardial fat has been previously shown to be related to cardio-metabolic risk factors and contribute to CAD; this could further extend the role of FGF21 as a biomarker for cardiovascular risk (72). Obesity and pericardial fat are also associated with the presence and the severity of atrial fibrillation (106), and an association between elevated FGF21 serum levels and atrial fibrillation has been shown independently of risk factors, such as BMI, presence of hypertension, and levels of highsensitivity C-reactive protein (33).…”

Section: Association Of Fgf21 With Cardiovascular Risk and Atherosclementioning

confidence: 92%

Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21

Domouzoglou

Naka

Vlahos

et al. 2015

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Early detection of risk factors for enhanced primary prevention and novel therapies for treating the chronic consequences of cardiovascular disease are of the utmost importance for reducing morbidity. Recently, fibroblast growth factors (FGFs) have been intensively studied as potential new molecules in the prevention and treatment of cardiovascular disease mainly attributable to metabolic effects and angiogenic actions. Members of the endocrine FGF family have been shown to increase metabolic rate, decrease adiposity, and restore glucose homeostasis, suggesting a multiple metabolic role. Serum levels of FGFs have been associated with established cardiovascular risk factors as well as with the severity and extent of coronary artery disease and could be useful for prediction of cardiovascular death. Furthermore, preclinical investigations and clinical trials have tested FGF administration for therapeutic angiogenesis in ischemic vascular disease, demonstrating a potential role in improving angina and limb function. FGF21 has lately emerged as a potent metabolic regulator with multiple effects that ultimately improve the lipoprotein profile. Early studies show that FGF21 is associated with the presence of atherosclerosis and may play a protective role against plaque formation by improving endothelial function. The present review highlights recent investigations suggesting that FGFs, in particular FGF21, may be useful as markers of cardiovascular risk and may also serve as protective/therapeutic agents in cardiovascular disease.

show abstract

Section: Association Of Fgf21 With Cardiovascular Risk and Atherosclementioning

confidence: 92%

Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21

Domouzoglou

Naka

Vlahos

et al. 2015

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

“…Recent clinical studies have reported correlations between serum FGF21 levels and cardiovascular disease, such as hypertension (165), coronary artery disease (166, 167), acute myocardial infarction (168), atrial fibrillation (169) and atrial fibrosis (170). In patients with end-stage heart failure, serum and cardiac levels of FGF21 are significantly elevated (159), and circulating FGF21 concentrations correlate with cardiac hypertrophy and diastolic dysfunction (171).…”

Section: The Effects Of Endocrine Fibroblast Growth Factors On the Heartmentioning

confidence: 99%

Cardiac actions of fibroblast growth factor 23

Faul

2017

Bone

View full text Add to dashboard Cite

Fibroblast growth factors (FGF) are mitogenic signal mediators that induce cell proliferation and survival. Although cardiac myocytes are post-mitotic, they have been shown to be able to respond to local and circulating FGFs. While precise molecular mechanisms are not well characterized, some FGF family members have been shown to induce cardiac remodeling under physiologic conditions by mediating hypertrophic growth in cardiac myocytes and by promoting angiogenesis, both events leading to increased cardiac function and output. This FGF-mediated physiologic scenario might transition into a pathologic situation involving cardiac cell death, fibrosis and inflammation, and eventually cardiac dysfunction and heart failure. As discussed here, cardiac actions of FGFs - with the majority of studies focusing on FGF2, FGF21 and FGF23 - and their specific FGF receptors (FGFR) and precise target cell types within the heart, are currently under experimental investigation. Especially cardiac effects of endocrine FGFs entered center stage over the past five years, as they might provide communication routes that couple metabolic mechanisms, such as bone-regulated phosphate homeostasis, or metabolic stress, such as hyperphosphatemia associated with kidney injury, with changes in cardiac structure and function. In this context, it has been shown that elevated serum FGF23 can directly tackle cardiac myocytes via FGFR4 thereby contributing to cardiac hypertrophy in models of chronic kidney disease, also called uremic cardiomyopathy. Precise characterization of FGFs and their origin and regulation of expression, and even more importantly, the identification of the FGFR isoforms that mediate their cardiac actions should help to develop novel pharmacological interventions for heart failure, such as FGFR4 inhibition to tackle uremic cardiomyopathy.

show abstract

“…Data from Yan et al 2015, Zhang et al 2015a media thickness (Chow et al 2013) in T2DM (type 2 diabetes mellitus) patients. FGF21 level was also increased in atrial fibrillation (AF) patients and was shown to be an independent risk factor for AF (Han et al 2015). In the cases of non-alcoholic fatty liver disease (NAFLD) and CAD, the serum FGF21 was associated with an adverse lipid profile and also showed a positive correlation with total cholesterol (TC) and triglycerides (TG) (Shen et al 2013).…”

Section: Clinical Evidence Of the Association Between Fgf21 And Cardimentioning

confidence: 99%

Effects of fibroblast growth factor 21 on the heart

Tanajak¹,

Chattipakorn²

2015

Journal of Endocrinology

View full text Add to dashboard Cite

Fibroblast growth factor 21 (FGF21) is a novel polypeptide ligand that has been shown to be involved in several physiological and pathological processes including regulation of glucose and lipids as well as reduction of arteriosclerotic plaque formation in the great vessels. It has also been shown to exert cardioprotective effects in myocardial infarction, cardiac ischemiareperfusion injury, cardiac hypertrophy and diabetic cardiomyopathy. Moreover, FGF21 protects the myocardium and great arteries by attenuating remodeling, inflammation, oxidative stress and also promoting the energy supply to the heart through fatty acid b-oxidation. This growing evidence emphasizes the important roles of FGF21 in cardioprotection. This review comprehensively summarizes and discusses the consistent and inconsistent findings regarding the beneficial effects of FGF21 on the heart available from both basic research and clinical reports. The details of the signaling, biological and pharmacological effects of FGF21 with regard to its protection of the heart are also presented and discussed in this review.

show abstract

Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients

Cited by 33 publications

References 34 publications

Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21

Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21

Cardiac actions of fibroblast growth factor 23

Effects of fibroblast growth factor 21 on the heart

Contact Info

Product

Resources

About